Kengreal

Cardiac MattersCangrealor is the first FDA-approved P2Y12 inhibitor.
FDA OKs antiplatelet for use during heart procedureFDA has approved cangrelor (Kengreal, The Medicines Company) for reducing the risk of periprocedural thrombotic events in patients undergoing percutaneous coronary intervention.